Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §3

Sermorelin — clinical evidence

Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.

Document identifier
CEI-MN-022/3
Series
Compound monograph
Version
3.3
Published
15 Feb 2026
Last reviewed
15 Jun 2026
Next review
15 Jun 2028
Identifier
10.71829/cei.mono.22
Certainty
Low
Cycle
2026 Q1

§3Clinical evidence

Assessed outcomes for SermorelinPoint estimates with confidence intervals for each contributing study, plotted against the line of no effect.0.00.20.40.60.81.0Standardised direction and relative magnitude of the recorded effectIndicationEffect as recordedGH axis1 trial · ModeratePeak stimulated growth hormone response…Ageing0 trials · Very lowNo randomised human evidence identified
Moderate or high certaintyLow or very low certainty
Figure 3. Illustrative. Assessed outcomes plotted on a common standardised axis so that direction and relative magnitude can be compared at a glance. The estimates are not on a common natural scale and the intervals are the Institute's standardised representation of the reported precision, not the published confidence intervals. Published intervals appear in the per-indication extracts and in the text below.

§3.1Growth hormone deficiency and growth-hormone secretagogue pharmacology

Anchor outcome. Peak stimulated growth hormone.

Effect as recorded. Peak stimulated growth hormone response used diagnostically; a peak below 5 µg/L after sermorelin supports pituitary rather than hypothalamic origin of deficiency; diagnostic performance, not an efficacy estimate.[1,2]

Certainty. Moderate certainty The evidence base supports a diagnostic application. The Institute found no adequately powered randomised trial supporting any therapeutic body-composition or anti-ageing application.

Contributing trials. SERM-DIAGNOSTIC. Full structured abstracts are published for each.

Full evidence extract for growth hormone deficiency and growth-hormone secretagogue pharmacology · Indication assessment

§3.2Biological ageing and healthspan endpoints

Anchor outcome. Epigenetic age acceleration.

Effect as recorded. No randomised human evidence identified; —.[2,3]

Certainty. Very low certainty Marketing claims in this indication are not supported by any trial the Institute has been able to locate.

Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.

Full evidence extract for biological ageing and healthspan endpoints · Indication assessment

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12(2):139–157. doi:10.2165/00063030-199912020-00007 · PMID 18031173
  2. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375 · PMID 18052660
  3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism 2006;91(3):799–805. doi:10.1210/jc.2005-1536 · PMID 16352683

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Compound Evidence Institute · CEI-MN-022/3 · https://compoundevidence.com/monographs/sermorelin/clinical-evidence/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.